Director AstraZeneca Gothenburg, Vastra Gotaland, Sweden
To successfully develop and apply predictive models for DIKI, three aspects are key: sufficient physiological relevance of the cell model, appropriate toxicity endpoints, and use of a fit-for-purpose approach. This presentation will discuss the utility of advanced in vitro models during drug discovery to predict DIKI and span from high-throughput multiparametric high content imaging in renal proximal tubular cells to time-course analysis of drug-induced kidney injury biomarkers in a proximal tubule-on-a-chip and exploration of multicellular kidney organoids. Furthermore, the need to expand the in vitro kidney toxicity assessment beyond small molecules to meet the growing interest in pharmaceutical industry to develop new drug modalities will be addressed.
